Chinese Journal of Dermatology ›› 2023, Vol. 56 ›› Issue (11): 1000-1007.doi: 10.35541/cjd.20230247

• Guidelines and Consensus • Previous Articles     Next Articles

Clinical pathway for the diagnosis and treatment of moderate to severe atopic dermatitis in China (2023): an expert consensus

Chinese Society of Dermatology, China Dermatologist Association   

  1. Chinese Society of Dermatology, China Dermatologist Association
  • Received:2023-04-28 Revised:2023-06-30 Online:2023-11-15 Published:2023-11-03
  • Contact: Song Zhiqiang; Gao Xinghua E-mail:drsongzq@hotmail.com; gaobarry@ hotmail.com

Abstract: 【Abstract】 In order to promote the standardization of diagnosis and treatment of moderate to severe atopic dermatitis in China, Chinese Society of Dermatology and China Dermatologist Association organized Chinese experts to establish a clinical pathway for the diagnosis and treatment of moderate to severe atopic dermatitis, through a combined approach of literature analysis, thematic discussion, and expert consultation. Firstly, the diagnosis, assessment, screening, and examination items for atopic dermatitis, as well as entry criteria for clinical pathway were described; secondly, the treatment principles, regimens and drugs for moderate to severe atopic dermatitis were elaborated, so were the efficacy assessment, follow-up and evaluation indicators, patient education and guidance, standards for pathway completion, pathway variation and its cause analysis; it was suggested that the course of induction treatment should not be less than 3 months, and the plan of maintenance treatment should be set for at least 3 - 6 months after the efficacy of induction treatment was achieved; finally, the management process and the clinical pathway form for the diagnosis and treatment of moderate to severe atopic dermatitis were listed in the appendixes.

Key words: Dermatitis, atopic, Diagnosis, Therapy, Remission induction, Clinical pathway